Better Growth Stock: CRISPR Therapeutics vs. Invitae
Now is a great time to load up on growth stocks because they may be among the first to benefit in the next bull market. We've already seen some of the biggest ones -- such as Amazon and Apple -- take off as indexes rallied in recent weeks. Buying these longtime winners could lift your portfolio, and if you want an additional boost, you could also add a few younger growth players to the mix. They're earlier in their stories, so if all goes well, they could truly pop -- and deliver great returns.
You'll find a lot of these candidates in the area of biotech, and two possibilities that come to mind right now are gene-editing company CRISPR Therapeutics (NASDAQ: CRSP) and genetic-testing specialist Invitae (NYSE: NVTA). The former is heading for a big milestone, and the latter could make a compelling recovery story. Which is the better growth stock to buy now? Let's find out.
Image source: Getty Images.
Source Fool.com
Apple Inc. Aktie
Leichtes Buy-Übergewicht bei Apple Inc. mit 73 Buy- gegenüber 7 Sell-Einschätzungen.
Ein positives, wenn auch nicht starkes, Potenzial für Apple Inc. mit einem Kursziel von 280 € im Vergleich zu 264.1 €.
